Get the Stockscreener App
3.795
0.66%
0.025
Pre-market:
3.80
0.005
+0.13%
Mannkind Corp stock is traded at $3.795, with a volume of 3.15M.
It is up +0.66% in the last 24 hours and down -7.89% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$3.77
Open:
$3.72
24h Volume:
3.15M
Relative Volume:
1.57
Market Cap:
$1.19B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
75.90
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
-0.39%
1M Performance:
-7.89%
6M Performance:
-45.94%
1Y Performance:
-25.73%
1-Day Range:
$3.65
$3.80
1-Week Range:
$3.63
$3.88
52-Week Range:
$3.63
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.795 | 1.19B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.54 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
511.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.51 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind stock hits 52-week low at $3.70 - Investing.com
Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga
Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus
MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com South Africa
MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia
Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech
MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com
MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada
MannKind to present inhaled insulin study at ADA event - Investing.com
Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23 - Yahoo Finance
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation - Investing.com Australia
MannKind To Present At Jefferies Global Healthcare Conference; Webcast At 2:35 PM ET - Nasdaq
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
Type 1 Diabetes Didn't Stop This INDYCAR Driver: Conor Daly Inspires Detroit Youth Before Grand Prix - Stock Titan
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha
MannKind stock touches 52-week low at $4.34 amid market shifts - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation - Investing.com
MannKind To Present At RBC Capital Markets Conference; Webcast At 8:00 AM ET - Nasdaq
Most adults with type 1 diabetes using inhaled insulin increase daily dose over 30 weeks - Healio
MannKind corp director Steven Binder sells $375,875 in stock By Investing.com - Investing.com Nigeria
MannKind EVP David Thomson sells shares worth $150,597 By Investing.com - Investing.com India
MannKind EVP David Thomson sells shares worth $150,597 - Investing.com
MannKind corp director Steven Binder sells $375,875 in stock - Investing.com
MannKind CMO steps down, transition plan set - Investing.com
MannKind to Present at Upcoming Investor Conferences - The Globe and Mail
MannKind Corporation (NASDAQ:MNKD) Q1 2025 Earnings Call Transcript - Insider Monkey
MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
MannKind: Q1 Earnings Snapshot - MySA
Earnings call transcript: MannKind Q1 2025 revenue beats, stock dips - Investing.com
MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Gr - GuruFocus
MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Growth | MNKD Stock News - GuruFocus
MannKind Corp Q1 2025 Earnings: EPS Meets Estimates at $0.04, Revenue Surpasses Expectations at $78 Million - GuruFocus
MannKind Corporation Reports First Quarter 2025 Financial Results - TradingView
MANNKIND CORP SEC 10-Q Report - TradingView
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Ex - GuruFocus
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 - The Globe and Mail
The Potential Rise in the Price of Mannkind Corp (MNKD) following insiders activity - knoxdaily.com
Solidion Technology Inc’s latest rating changes from various analysts - knoxdaily.com
MNKD (Mannkind Corp) may reap gains as insiders became active recently - knoxdaily.com
Mannkind Corp (MNKD) is looking forward to a strong quarter - Sete News
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):